Hong Kong VMS Group was founded in 2006 and since then has built close relationships with a handful of large anchor investors, including some of the largest families in Hong Kong. Apart from managing over USD 4.3 billion across its three in-house strategies – Private Equity, Real Estate and Structured Finance, it…
China In recent years, global pharma’s Business Development (BD) operations in Asia have evolved from primarily managing global agreements locally to engaging in more complex tasks like contract negotiation and due diligence. Servier’s Asia BD Head Cynthia Xin Wang explains how this shift reflects changing market dynamics and the growing importance…
China Since it was established in 1988, PhIRDA, an organization that groups together China’s pharma innovators, research institutions and investors has played an active role in the evolution of China’s biopharma landscape. Executive President Prof. Song Ruilin outlines the advances and some of the challenges and opportunities facing China’s biotech and…
Saudi Arabia Baxter Saudia Arabia GM Faisal BinDail shares some insights into the renal care specialist’s local manufacturing hub, the sole manufacturing site for peritoneal dialysis products in the Middle East, and the company’s plans to expand its reach in Saudi Arabia and the broader region. We aim to provide our…
Saudi Arabia Basel Al-Qahtani, General Manager of Boston Scientific Saudi Arabia, discusses how Boston Scientific has expanded its operations to establish a fully fledged regional headquarters in the kingdom. He outlines the company’s commitment to Saudi Arabia’s Vision 2030 agenda through public-private partnerships and potentially through accountable care organizations, and underlines the…
USA Johnson & Johnson has been building its medtech arm and creating a differentiated pipeline through strategic M&A, an approach that generated USD 30.4 billion in medical device sales last year, representing growth of 12.4 percent. The company has now acquired Shockwave Medical, bringing its IVL technology on board for USD…
Hong Kong After the Hong Kong Exchanges and Clearing Limited’s (HKEX) 2018 move to allow pre-revenue biotech companies to raise capital in Hong Kong under its Chapter 18A mechanism, biotech listings surged with pre-clinical companies chosing to list on HKEX as a means of accessing global capital, raising around HKD 118 billion…
India Sanjay Bhutani of Bausch & Lomb outlines why the medical devices sector in India is poised for substantial growth, bolstered by increased government support and a higher healthcare budget. He also explains how the 2023 National Medical Device Policy marks a significant shift towards recognizing the distinct needs of the…
USA The COVID-19 pandemic looked like a turning point for vaccines, but while R&D has made tremendous strides with ground-breaking platform technologies and mRNA, vaccines continue to attract fewer investments than areas such as oncology. As panel members at the “Reviewing Vaccine Pipeline Breakthroughs and Barriers” session during BIO’s recent CEO…
Saudi Arabia Maher Abouzeid outlines Medserve’s role as a healthcare projects incubator, focusing on identifying and filling gaps in healthcare services across the Middle East & Africa region. Their hands-on approach includes conducting market assessments, securing funding, and assembling operational teams. Abouzeid also explains the company’s latest venture, Ardens Health, the first…
USA At the American trade association’s latest CEO & Investor Conference, the board chair of the Biotechnology Innovation Organization (BIO) Ted W. Love discussed US policies and speculated about the impact of the upcoming American election on the industry while affirming that biotech continues to thrive in spite of recent challenges.…
Pharma Legal Handbook 1. Please describe the main cost containment policies in place in your country and their fundamental principles a. Pricing and impact of generic/biosimilar approval Currently there are no policies in place in this regard. b. Clawback/Payback/Discounts/Rebates In Portugal, the main mechanism for cost-containment is the prior evaluation, regulated…
See our Cookie Privacy Policy Here